卵巢癌
医学
单克隆抗体
肿瘤科
癌症
化疗
细胞毒性T细胞
内科学
抗药性
抗体
免疫学
癌症研究
生物
体外
生物化学
微生物学
作者
Eduardo González-Ochoa,Ana Veneziani,Amit M Oza
标识
DOI:10.1177/11795549231187264
摘要
Ovarian cancer is the second leading cause of death from gynecologic malignancies worldwide. Management of platinum-resistant disease is challenging and clinical outcomes with standard chemotherapy are poor. Over the past decades, significant efforts have been made to understand drug resistance and develop strategies to overcome treatment failure. Antibody drug conjugates (ADCs) are a rapidly growing class of oncologic therapeutics, which combine the ability to target tumor-specific antigens with the cytotoxic effects of chemotherapy. Mirvetuximab soravtansine is an ADC comprising an IgG1 monoclonal antibody against the folate receptor alpha (FRα) conjugated to the cytotoxic maytansinoid effector molecule DM4 that has shown promising clinical activity in patients with FR-α-positive ovarian cancer. This review summarizes current evidence of mirvetuximab soravtansine in platinum-resistant ovarian cancer, focusing on clinical activity, toxicity, and future directions.
科研通智能强力驱动
Strongly Powered by AbleSci AI